1. PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH RITUXIMAB VERSUS PLACEBO IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH TREATMENT‐NAÏVE FOLLICULAR LYMPHOMA (PERSPECTIVE). (June 2017) Authors: Rule, S.; Flinn, I.W.; Fowler, N.; Chen, R.; Kwei, L.; Beaupre, D.M.; Chu, A.D.; Gordon, L.I. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL). (June 2017) Authors: Tam, C.S.; Rule, S.; Le Gouill, S.; Vitolo, U.; Tsao, L.C.; Cavazos, N.; Beaupre, D.M.; Wang, M.L. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 421 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗